Patents by Inventor Barry J. Maurer

Barry J. Maurer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7785621
    Abstract: The present invention provides an edible composition for oral delivery of an active agent such as a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: August 31, 2010
    Assignee: Childrens Hospital Los Angeles
    Inventors: Barry J. Maurer, Charles Patrick Reynolds, David W. Yesair, Robert Travis McKee, Stephen W. Burgess, Walter A. Shaw
  • Patent number: 7780978
    Abstract: The present invention provides an edible composition for oral delivery of an active agent such as paclitaxel or a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: August 24, 2010
    Assignee: Childrens Hospital Los Angeles
    Inventors: Barry J. Maurer, Charles Patrick Reynolds, David W. Yesair, Robert Travis McKee, Stephen W. Burgess, Walter A. Shaw
  • Patent number: 7476692
    Abstract: The present invention provides stable aqueous solutions consisting essentially of: (a) a sphingolipid; (b) lactic acid; and (c) optionally a stabilizing agent; wherein the solution has a molar ratio of lactic acid to sphingolipid of 1:1 to 10:1. The present invention further provides an emulsion formulation consisting essentially of: (a) lactic acid; (b) a sphingolipid, wherein the sphingolipid is present in an amount of about 0.1 to about 30 mg/ml of emulsion; (b) optionally an isotonic agent; and (c) a phospholipid present in an amount of about 0.2 to about 200 mg/ml of emulsion. Methods of making and using the compositions are also provided.
    Type: Grant
    Filed: February 19, 2004
    Date of Patent: January 13, 2009
    Assignee: Childrens Hospital Los Angeles
    Inventors: Shanker Gupta, C. Patrick Reynolds, Barry J. Maurer, B. Rao Vishnuvajjala
  • Patent number: 7169819
    Abstract: A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR® EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: January 30, 2007
    Assignee: Childrens Hospital Los Angeles
    Inventors: Shanker Gupta, Barry J. Maurer, C. Patrick Reynolds, B. Rao Vishnuvajjala
  • Publication number: 20050271707
    Abstract: The present invention provides an edible composition for oral delivery of an active agent such as paclitaxel or a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.
    Type: Application
    Filed: June 29, 2005
    Publication date: December 8, 2005
    Inventors: Barry J. Maurer, Charles Patrick Reynolds, David W. Yesair, Robert Travis McKee, Stephen W. Burgess, Walter A. Shaw
  • Publication number: 20020183394
    Abstract: A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR® EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.
    Type: Application
    Filed: December 5, 2001
    Publication date: December 5, 2002
    Inventors: Shanker Gupta, Barry J. Maurer, C. Patrick Reynolds, B. Rao Vishnuvajjala
  • Patent number: 6368831
    Abstract: A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-generating retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) ceramide degredation inhibitor, such as compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors and/or 1-acylceramide synthesis inhibitors, (ii) sphingosine-1-phosphate synthesis inhibitors, and (iii) protein kinase C inhibitors. A preferred glucosyl ceramide synthesis inhibitor is 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingosine-1-phosphate synthesis inhibitor is D-erythro-N,N-dimethylsphingosine. A preferred protein kinase C inhibitor is L-threo-dihydrosphingosine.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: April 9, 2002
    Assignee: Childrens Hospital Los Angeles
    Inventors: Barry J. Maurer, C. Patrick Reynolds
  • Patent number: 6352844
    Abstract: A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-generating retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) ceramide degredation inhibitor, such as compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors, (ii) sphingosine-1-phosphate synthesis inhibitors, and (iii) protein kinase C inhibitors. A preferred glucosyl ceramide synthesis inhibitor is 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingosine-1-phosphate synthesis inhibitor is D-erythro-N,N-dimethylsphingosine. A preferred protein kinase C inhibitor is L-threo-dihydrosphingosine.
    Type: Grant
    Filed: June 28, 1999
    Date of Patent: March 5, 2002
    Assignees: Childrens Hospital Los Angeles, John Wayne Cancer Institute
    Inventors: Barry J. Maurer, Myles Cabot, C. Patrick Reynolds